Sanofi
SNY
$59.15
$1.452.51%
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 40.55B | 45.79B | |
| Total Other Revenue | -- | -- | 3.43B | 2.91B | |
| Total Revenue | -- | -- | 43.98B | 48.70B | |
| Cost of Revenue | -- | -- | 13.53B | 14.85B | |
| Gross Profit | -- | -- | 30.45B | 33.85B | |
| SG&A Expenses | -- | -- | 9.70B | 11.46B | |
| Depreciation & Amortization | -- | -- | 2.05B | 2.20B | |
| Other Operating Expenses | -- | -- | 4.04B | 3.31B | |
| Total Operating Expenses | -- | -- | 36.30B | 38.93B | |
| Operating Income | -- | -- | 7.68B | 9.77B | |
| Income Before Tax | -- | -- | 6.54B | 12.06B | |
| Income Tax Expenses | -- | -- | 1.09B | 2.33B | |
| Earnings from Continuing Operations | -- | -- | 5.46K | 9.73K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -38.53M | -100.47M | |
| Net Income | -- | -- | 5.78B | 9.63B | |
| EBIT | -- | -- | 7.68B | 9.77B | |
| EBITDA | -- | -- | 11.02B | 13.16B | |
| EPS Basic | -- | -- | 4.62 | 7.69 | |
| Normalized Basic EPS | -- | -- | 0.78 | 1.59 | |
| EPS Diluted | -- | -- | 4.61 | 7.68 | |
| Normalized Diluted EPS | -- | -- | 0.78 | 1.59 | |
| Average Basic Shares Outstanding | -- | -- | 5.00B | 5.01B | |
| Average Diluted Shares Outstanding | -- | -- | 5.01B | 5.01B | |
| Dividend Per Share | -- | -- | 4.05 | 3.64 | |
| Payout Ratio | -- | -- | -- | -- | |
